Effects of gamma-vinyl GABA. 1981

G P Tell, and P J Schechter, and J Koch-Weser, and P Cantiniaux, and J P Chabannes, and P A Lambert

UI MeSH Term Description Entries
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000614 Aminocaproates Amino derivatives of caproic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the amino caproic acid structure. Aminocaproic Acids,Aminocaproic Acid Derivatives,Aminohexanoates,Aminohexanoic Acid Derivatives,Aminohexanoic Acids,Acid Derivatives, Aminocaproic,Acid Derivatives, Aminohexanoic,Acids, Aminocaproic,Acids, Aminohexanoic,Derivatives, Aminocaproic Acid,Derivatives, Aminohexanoic Acid
D020888 Vigabatrin An analogue of GAMMA-AMINOBUTYRIC ACID. It is an irreversible inhibitor of 4-AMINOBUTYRATE TRANSAMINASE, the enzyme responsible for the catabolism of GAMMA-AMINOBUTYRIC ACID and is used as an anticonvulsant. (From Martindale The Extra Pharmacopoeia, 31st ed) gamma-Vinyl-gamma-Aminobutyric Acid,Sabril,Sabrilex,gamma-Vinyl-GABA,gamma Vinyl GABA,gamma Vinyl gamma Aminobutyric Acid

Related Publications

G P Tell, and P J Schechter, and J Koch-Weser, and P Cantiniaux, and J P Chabannes, and P A Lambert
January 1985, General pharmacology,
G P Tell, and P J Schechter, and J Koch-Weser, and P Cantiniaux, and J P Chabannes, and P A Lambert
January 1989, Epilepsia,
G P Tell, and P J Schechter, and J Koch-Weser, and P Cantiniaux, and J P Chabannes, and P A Lambert
June 1981, Biochemical pharmacology,
G P Tell, and P J Schechter, and J Koch-Weser, and P Cantiniaux, and J P Chabannes, and P A Lambert
June 1990, European journal of pharmacology,
G P Tell, and P J Schechter, and J Koch-Weser, and P Cantiniaux, and J P Chabannes, and P A Lambert
October 1985, Neuropharmacology,
G P Tell, and P J Schechter, and J Koch-Weser, and P Cantiniaux, and J P Chabannes, and P A Lambert
September 1979, Pharmacology, biochemistry, and behavior,
G P Tell, and P J Schechter, and J Koch-Weser, and P Cantiniaux, and J P Chabannes, and P A Lambert
July 1982, Pharmacology, biochemistry, and behavior,
G P Tell, and P J Schechter, and J Koch-Weser, and P Cantiniaux, and J P Chabannes, and P A Lambert
May 1979, Journal of neurochemistry,
G P Tell, and P J Schechter, and J Koch-Weser, and P Cantiniaux, and J P Chabannes, and P A Lambert
March 1984, Lancet (London, England),
G P Tell, and P J Schechter, and J Koch-Weser, and P Cantiniaux, and J P Chabannes, and P A Lambert
January 1988, Journal of neural transmission,
Copied contents to your clipboard!